12,962 Shares in Exelixis, Inc. $EXEL Acquired by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, Holdings Channel.com reports. The firm bought 12,962 shares of the biotechnology company’s stock, valued at approximately $568,000.

Several other institutional investors have also added to or reduced their stakes in EXEL. Allworth Financial LP increased its stake in shares of Exelixis by 159.7% in the 4th quarter. Allworth Financial LP now owns 7,451 shares of the biotechnology company’s stock worth $327,000 after purchasing an additional 4,582 shares in the last quarter. Ameritas Advisory Services LLC bought a new position in shares of Exelixis in the fourth quarter worth about $1,502,000. Legacy Financial Advisors Inc. bought a new position in shares of Exelixis in the fourth quarter worth about $223,000. HighPoint Advisor Group LLC purchased a new position in shares of Exelixis during the 4th quarter valued at about $200,000. Finally, Swiss Life Asset Management Ltd lifted its position in shares of Exelixis by 53.0% during the 4th quarter. Swiss Life Asset Management Ltd now owns 18,415 shares of the biotechnology company’s stock valued at $807,000 after buying an additional 6,381 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Dana Aftab sold 47,918 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the completion of the transaction, the executive vice president directly owned 616,106 shares of the company’s stock, valued at approximately $27,416,717. This represents a 7.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director George Poste sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $45.71, for a total value of $2,742,600.00. Following the transaction, the director owned 118,832 shares of the company’s stock, valued at $5,431,810.72. This represents a 33.55% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 382,811 shares of company stock valued at $17,014,813. 2.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. TD Cowen increased their target price on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Morgan Stanley upped their price target on shares of Exelixis from $49.00 to $50.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Stifel Nicolaus increased their price objective on shares of Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Finally, Truist Financial raised shares of Exelixis to a “strong-buy” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $47.35.

Exelixis Price Performance

Exelixis stock opened at $51.10 on Friday. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $51.63. The firm’s 50 day moving average price is $44.13 and its 200-day moving average price is $43.44. The stock has a market cap of $12.84 billion, a P/E ratio of 16.98, a PEG ratio of 1.08 and a beta of 0.38.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.12. The company had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. Exelixis’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the company posted $0.55 earnings per share. As a group, equities analysts expect that Exelixis, Inc. will post 3.15 EPS for the current year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.